AlzeCure Pharma AB ALZCUR
OMXSTO · Sweden · Health Technology
SEK 7.26-0.20 (-2.68%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
STOCKHOLM, SE / ACCESS Newswire / September 22, 2026 / AB (publ) (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, today announced that the company will participate and present at Swiss Nordic Bio 2026 in Zurich on October 1, a partnering and investor conference connecting Nordic, Swiss and Austrian companies in biotech, medtech and pharma with global investors and industry representatives.At the event, CEO Martin
STOCKHOLM, SE / ACCESS Newswire / September 18, 2026 / AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, today announced that an updated company presentation in English is now available. In the presentation, CEO Martin Jönsson provides an updated view of the company following the recently signed collaboration and outlicensing agreements with US-based Eli Lilly and Denmark-based Quan
STOCKHOLM, SE / ACCESS Newswire / September 8, 2026 / AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6) , which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, today announced that the company will participate in Aktiespararna's Aktiedagen in Stockholm event on September 15. CEO Martin Jönsson will give a corporate presentation and provide an update on the company's recently announced out-licensing and collaboration agreements with Eli
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.